Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

Eli Lilly announced clinical trial results for retatrutide, demonstrating that study participants lost an average of 70 lbs over 80 weeks. The drug shows greater efficacy than competing obesity medications Zepbound and Wegovy, positioning it as a more powerful next-generation treatment option.